Federated Hermes’s BridgeBio Pharma BBIO Stock Holding History

Federated Hermes’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39M	Sell	523,678 -64,756	-11%	-$4.54M	0.06%	322
2026 Q1	$43.7M	Buy	588,434 +1,639	+0.3%	+$119K	0.07%	295
2025 Q4	$44.9M	Buy	586,795 +162,100	+38%	+$10.6M	0.08%	281
2025 Q3	$22.1M	Buy	424,695 +147,108	+53%	+$7.17M	0.04%	409
2025 Q2	$12M	Buy	+277,587	New	+$10.1M	0.02%	528
2024 Q3	–	Sell	-4,500	Closed	-$114K	–	2063
2024 Q2	$114K	Sell	4,500 -75,028	-94%	-$2.05M	﹤0.01%	1552
2024 Q1	$2.46M	Sell	79,528 -367,643	-82%	-$12.5M	0.01%	880
2023 Q4	$18.1M	Sell	447,171 -18,605	-4%	-$559K	0.04%	413
2023 Q3	$12.3M	Buy	465,776 +31,855	+7%	+$904K	0.03%	487
2023 Q2	$7.46M	Buy	433,921 +178,353	+70%	+$2.68M	0.02%	607
2023 Q1	$4.24M	Buy	+255,568	New	+$2.98M	0.01%	741
2019 Q3	–	Sell	-5,000	Closed	-$135K	–	2206
2019 Q2	$135K	Buy	+5,000	New	+$136K	﹤0.01%	1581

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Federated Hermes's BBIO Position: Q2 2026 in Review

Federated Hermes reduced its BridgeBio Pharma (BBIO) stake by 11% in Q2 2026, selling an estimated $4.54M and leaving 523,678 shares worth $39M. The position accounts for 0.06% of the portfolio, ranked #322.

Federated Hermes first reported a position in BBIO in Q2 2019 and has held it in 12 quarters since. The position peaked at $44.9M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Federated Hermes held 523,678 shares of BridgeBio Pharma worth $39M as of Q2 2026.
Federated Hermes sold 64,756 BridgeBio Pharma shares in Q2 2026, an estimated $4.54M.
BridgeBio Pharma made up 0.06% of Federated Hermes's portfolio in Q2 2026, its #322 holding.
Federated Hermes first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 12 quarters since.
Federated Hermes's BridgeBio Pharma position peaked at $44.9M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.